Abhishek Tripathi
Overview
Explore the profile of Abhishek Tripathi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jaime-Casas S, Barragan-Carrillo R, Tripathi A
Curr Opin Oncol
. 2024 Jul;
36(5):421-429.
PMID: 39007183
Purpose Of Review: Antibody-drug conjugates (ADCs) are designed to carry cytotoxic payloads and deliver them to specific molecular targets within tumor cells. Several ADCs are already approved with many more...
12.
Ebrahimi H, Dizman N, Meza L, Malhotra J, Li X, Dorff T, et al.
Nat Med
. 2024 Jun;
30(9):2576-2585.
PMID: 38942995
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect...
13.
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, et al.
Nutrients
. 2024 Jun;
16(11).
PMID: 38892563
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to...
14.
Ebrahimi H, Megally S, Plotkin E, Shivakumar L, Salgia N, Zengin Z, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248739.
PMID: 38683608
Importance: While an overwhelming majority of patients diagnosed with cancer express willingness to participate in clinical trials, only a fraction will enroll onto a research protocol. Objective: To identify critical...
15.
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, et al.
Eur Urol Focus
. 2024 Apr;
10(5):812-817.
PMID: 38580524
Background And Objective: The impact of time of metastasis onset with respect toprimary renal cell carcinoma (RCC) diagnosis on survival outcomes is not well characterized in the era of immune...
16.
Pal S, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama B, et al.
Eur Urol
. 2024 Apr;
87(2):271-274.
PMID: 38580518
No abstract available.
17.
Park J, Chu A, Li J, Ali A, McKay R, Hwang C, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300567.
PMID: 38579192
Purpose: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the...
18.
Choudhury A, Kwak L, Cheung A, Allaire K, Marquez J, Yang D, et al.
Cancer Immunol Res
. 2024 Mar;
12(6):704-718.
PMID: 38552171
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P)...
19.
Khan A, Tripathi A, Gandhi M, Bellare J, Srivastava R
J Biomed Mater Res A
. 2024 Mar;
112(9):1612-1626.
PMID: 38545952
Nanotheranostic-based photochemotherapies with targeted drug delivery have considerably surfaced in cancer therapy. In the presented work, polyethyleneimine-coated upconversion nanoparticles were engineered to conjugate covalently with doxorubicin. Upconversion nanoparticles (UCNP)-Doxorubicin (DOX)/synthesized...
20.
Zengin Z, Henderson N, Park J, Ali A, Nguyen C, Hwang C, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
PMID: 38383885
Background: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context...